Login to Your Account

Janssen executes 2nd Macrogenics bispecifics deal; $75M up front

By Michael Fitzhugh
Staff Writer

Wednesday, May 18, 2016

Macrogenics Inc. shares climbed 16.7 percent on Wednesday as Janssen Biotech Inc. extended its collaboration with the company, agreeing to pay $75 million up front for a global license to MGD015.

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription